Melbourne Australia:  Starpharma Holdings Ltd (ASX: SPL; OTCQX: SPHRY) today released its Appendix 4C – Quarterly Cashflow report for the period ended 31 March 2013.

The cash balance at 31 March was $35.9 million following the receipt of a $5.4 million R&D tax incentive refund. This represents a net increase of $2.7 million on the previous quarter.

On 3 April, Starpharma announced positive results for its Phase 2 clinical trial for the prevention of recurrence of bacterial vaginosis (BV).  The trial, involving 205 women, showed that 1% VivaGel^® demonstrated reduced risk of recurrent BV and delayed time to first recurrence.  VivaGel^® was safe and well tolerated by trial participants over the 16 week treatment period and high levels of patient satisfaction were reported with VivaGel^®.  On the strength of these results, Starpharma is planning to advance VivaGel^® to Phase 3 studies for the prevention of recurrence indication, following input from FDA and other regulatory authorities.

Following the release in November 2012 of the Phase 3 results for VivaGel^® for BV treatment, the company continues to make good progress with exploring alternative claim strategies, such as symptomatic relief and additional markets.  The recent Phase 2 symptomatic results have added to this data set. These will be the subject of further discussions with the relevant authorities in coming few months and based on that regulatory feedback the possibility of making submissions based on these strategies will be pursued.

In other reported activity during the quarter, Starpharma signed a collaboration program with Makhteshim Agan, one of the world’s leading manufacturers and distributors of branded off-patent crop products.  Starpharma is applying its Priostar^® dendrimer technology to novel crop formulations across Makhteshim Agan’s extensive product portfolio.

Download ASX Announcement: Appendix 4C - Quarterly Cashflow Report ( pdf file, 139kb)